山东新华制药厂与中国医学科学院药物研究所共同研制的尼莫地平已通过鉴定,并于1989年9月正式生产投放市场。尼莫地平为1,4双氢吡啶类第一代钙通道阴滞剂。临床应用于缺血性脑血管病,偏头痛,蛛网膜下腔出血所引起的脑血管痉挛,突发性耳聋,轻、中度高血压病等。(本 Nimodipine, jointly developed by Shandong Xinhua Pharmaceutical Factory and Institute of Materia Medica, Chinese Academy of Medical Sciences, has passed the appraisal and was put on the market formally in September 1989. Nimodipine is the first generation of 1,4-dihydropyridine calcium channel blocker. Clinical application of ischemic cerebrovascular disease, migraine, subarachnoid hemorrhage caused by cerebral vasospasm, sudden deafness, mild to moderate hypertension and so on. (this